AveragePenny
1年前
$LEON Leone Asset Management’s Subsidiary JP Anderson Signs MOU
https://www.accesswire.com/785745/leone-asset-managements-subsidiary-jp-anderson-signs-mou
CLEARWATER, FL / ACCESSWIRE / September 20, 2023 / Today, Leone Asset Management (OTC PINK:LEON) Subsidiary JP Anderson, Ltd., announced that they have entered a Memorandum of Understanding (MOU) with the Nyingohun landholding family of Molendeh Village in the Nyawa Section of the Gbo Chiefdom in Sierra Leone, West Africa.
The MOU agreement between the two parties is to undertake the business of quarrying, leading to the crushing of stone for infrastructure development in Sierra Leone and other countries in West Africa. JP Anderson will be operating a 500+-acre quarry location in the Bbo Chiefdom in Sierra Leone. The quarry location has more than 100 million tons of stone to be crushed. The agreement is in place for 20 years with an additional 25-year option. The parties anticipate beginning operations in the first quarter of 2024.
James Price, Chairman and CEO of Leone Asset, stated, we anticipate beginning operations with a 350 ton per hour crushing plant and operating six days per week with two eight hour shifts daily. We plan on doubling production in both year 2 and year 3 depending on demand for the finished product. For all product marketing and quarry information Leone will be building out a separate website (LeoneStone.com) and will be selling all products as Leone Stone & Gravel.
This opportunity and corporate expansion will add tremendous share-holder value and will allow Leone Asset to participate with Sierra Leone and other Sub-Saharan countries with some of the World's largest infrastructure development over the next fifty years."
AskMuncher
4年前
$LEON Leonteq Opens Milan Office
Press Release | 10/12/2020
Leonteq AG (SIX: LEON) expands its presence in Europe with the opening of an office in Milan to more closely serve the Italian market.
The move to Milan is part of Leonteq's planned expansion to increase its global footprint, and a natural next step to support the business growth and meet the needs of its client base as its activity in Italy continues to strengthen. Over the years, Italy has become a promising market for structured products with over 1,000 Leonteq certificates listed on EuroTLX and SeDeX. In particular, Leonteq has offered certificates on the EuroTLX exchange since 2016 and issued its first product on SeDeX just a year ago in October 2019. The continued demand for structured products in Italy also led to the first launch on EuroTLX of products issued by EFG International via Leonteq's technology platform earlier this year.
Leonteq's onshore business in Milan, which commenced at the beginning of October 2020, is managed by Marco Occhetti, Managing Director and Head South Europe at Leonteq. Marco joined Leonteq in 2015 and has built up the offering for the Italian market over the past years. Before joining Leonteq, Marco Occhetti led the private banking investment solutions business in Ticino and Southern Europe at Commerzbank for six years and was Vice President of equity derivatives at Deutsche Bank from 2007 to 2009, where he serviced institutional clients. Prior to this, he worked at Morgan Stanley in the institutional equity derivatives division and at Commerzbank.
Lukas Ruflin, CEO of Leonteq, stated: "We are delighted to open our office in Italy. This expansion underscores our commitment to the Italian market as well as the importance of this region for Leonteq."
"We are excited to finally have a physical presence in Italy and work more closely with our clients and partners to expand our structured product offering and services", added Marco Occhetti.
LEONTEQ
Leonteq is a Swiss company active in the finance and technology sector with a focus on the structured products segment. Based on proprietary modern technology, the company offers derivative investment products and services and predominantly covers the capital protection, yield enhancement and participation product classes. Leonteq acts as both a direct issuer of its own products and as a partner to other financial institutions. Leonteq further enables life insurance companies to produce capital-efficient, unit-linked pension products with guarantees. The company has offices and subsidiaries in 11 countries, through which it serves over 50 markets. Leonteq AG is listed on the SIX Swiss Exchange (SIX: LEON). www.leonteq.com
DISCLAIMER
This press release issued by Leonteq AG (the "Company") serves for information purposes only and does not constitute research. This press release and all materials, documents and information used therein or distributed in the context of this press release do not constitute or form part of and should not be construed as, an offer (public or private) to sell or a solicitation of offers (public or private) to purchase or subscribe for shares or other securities of the Company or any of its affiliates or subsidiaries in any jurisdiction or an inducement to enter into investment activity in any jurisdiction, and may not be used for such purposes. Copies of this press release may not be made available (directly or indirectly) to any person in relation to whom the making available of the press release is restricted or prohibited by law or sent to countries, or distributed in or from countries, to, in or from which this is restricted or prohibited by law.
This press release may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "target" "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the Company or any of its affiliates or subsidiaries and those explicitly or implicitly presumed in these statements. These factors include, but are not limited to: (1) general market, macroeconomic, governmental and regulatory trends, (2) movements in securities markets, exchange rates and interest rates and (3) other risks and uncertainties inherent in our business. In addition, currently, it is very difficult to provide a meaningful prediction on how the governmental actions in response to the ongoing outbreak of a novel coronavirus disease (COVID-19) and other COVID-19 related factors will affect Leonteq's operations and how long such measures will remain in place. The COVID-19 outbreak has caused, and may continue to cause, uncertainty, economic instability and a significant decrease of total economic output in the affected areas and globally. The impact of the COVID-19 outbreak on the general economic environment in the markets in which Leonteq operates remain uncertain and could be significant. Against the background of these uncertainties, you should not rely on forward-looking statements. Neither the Company nor any of its affiliates or subsidiaries or their respective bodies, executives, employees and advisers assume any responsibility to prepare or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this press release or to adapt them to any change in events, conditions or circumstances, except as required by applicable law or regulation.
skipsvalue
7年前
Go Epic Health to Begin Next Round of Clinical Studies for Cholesterade®Press Release | 03/21/2018
Leone Asset Management announces that their subsidiary Go Epic Health is beginning their next clinical study for Cholesterade®
St. Petersburg, FL, March 21, 2018 (GLOBE NEWSWIRE) -- James Price, CEO of Go Epic Health, stated, “We are extremely excited to begin the next round of clinical studies on Cholesterade®. When Dr. Cade first created the product he conducted case studies at the University of Florida and had amazing results in the study. Recently, Dr. Richard Goldfarb conducted a proof of concept study to once again prove the efficacy of Cholesterade® on lowering cholesterol and also experienced amazing and similar results as Dr. Cade. The next round of studies will be a much larger scale as well as being conducted in a multi-center program.”
The research study is to validate the use of Cholesterade® to improve lipid profiles of individuals and examine the cardiovascular benefits of this reduction in lipids.
The research study will involve the use of human subjects and thus will need to be in a clinical setting. It will also require prior IRB approval. We intend to use Western IRB for study protocol approval. The study will be conducted in several clinic locations in the Memphis, Tennessee area and will use Cleveland Heart Labs advanced Lipid screen for lab draws and test results.
The genesis of this study is based on a previous case study conducted on Cholesterade® namely - Effect of two Dietary Soluble Fibers on Cholesterol and Triglyceride Concentrations in Human Plasma - which showed robust improvement in Lipid profiles of test subjects within 4 weeks of use including LDL, HDL, Total Cholesterol and Triglycerides.
We want to build on the results of that study and further explore the medium and long-term effects of Cholesterade® on reduction in lipids and improvement in overall lipid profile as a cardio-protective mechanism for improved clinical outcomes in test subjects.
This new proposed study will involve human subjects who will have baseline Total Cholesterol, LDL, HDL, TG and advanced Lipids. These advanced Lipids and Arterial Inflammatory markers have been shown to be elevated in subjects vulnerable to an impending cardiovascular adverse event.
In addition to the standard Lipid profile mentioned above and as tested in the previous study, we will be testing for F2-IsoPs, OxLDL - which correlate with lifestyle concerns. ADMA/SDMA, Microalbumin, hsCRP - which correlate with development of metabolic or cardiovascular disease, Lp-PLA2 Activity, MPO - which correlate with formation of vulnerable plaque and increased risk for an adverse event.
We will also check for advanced Lipid particles - Apolipoprotein B (ApoB) and A1 (ApoA1), Small-Dense LDL (sdLDL), Lipoprotein (a) (Lp(a)) and HDL2b – which address additional risk factors for Cardiovascular disease including the number of atherogenic particles, the size of these particles and the inherent risk of developing CVD.
These labs will be drawn at baseline before the start of the study period. After signing a consent form to be a part of the study protocol, these subjects will then be randomized into the Cholesterade® or Placebo group for a period of 12 months without changing any lipid lowering therapy. An attempt will also be made to keep medication profiles unchanged over the course of the study period.
These subjects will undergo a 3-month, 6-month, 9-month and 12-month follow up clinic visits and have the same labs drawn on each visit.
We will longitudinally follow these patients and also look for cardiovascular outcomes including new onset Diabetes, Hypertension, Cardiovascular event (defined as Unstable Angina, NSTEMI or STEMI) and Ischemic Stroke during the study period.
We will try to propensity match the placebo and treatment groups. We will look to minimize confounding. The Lipid profiles and change in lipid particle values will be statistically evaluated. We will also compare cardiovascular outcomes as defined in the protocol between the placebo and treatment groups.
We will also look at adverse reactions and side effect profile of the product during this research study.
The results will be published in a peer-reviewed journal and be available on PubMed for review and viewing. We expect to validate the findings of the previous case series and add to the value of Cholesterade® by showing improved lab results not only in the standard lipid panel but advanced lipids and inflammatory markers which are more reliable markers of Cardiovascular disease risk. This will put Cholesterade® on the forefront of Cardiovascular disease prevention as an over the counter non-medicinal product and further enhance its market share.
We will also explore the possibility of doing a Meta-analysis of clinical data involving the use of Cholesterade® product in various clinical outcomes. This will evolve as more trials are conducted using the Cholesterade® product.
About Leone Asset Management
Leone Asset Management, Inc., is a multi-national, multi-industry conglomerate with subsidiary companies that operate in Health and Wellness, Infrastructure development and agriculture management. For additional information, visit: www.leoneasset.com.
About Go Epic Health
Go Epic Health, a Leone Asset Management subsidiary, is a nutritional product holding company which owns the intellectual property and worldwide manufacturing and distribution rights to Cholesterade®, a natural cholesterol reducing product created by the late Dr. Robert Cade, creator of Gatorade®. Go Epic Health markets and distributes Cholesterade® as well as other new and innovative consumer goods through the nation's largest retail pharmacy chain stores, drug and health food stores and product specific catalogs. For further information, please visit www.goepichealth.com and www.cholesterade.com.
Forward-Looking Statements Disclosure:
This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," " plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matter that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.
Woody Junot President Go Epic Health (727) 581-1500 wjunot@goepichealth.com
skipsvalue
8年前
Nov 18th News Release
Leone Asset Management Acquires Controlling Interest in Go Epic Health
November 18, 2016
BELLAIR BLUFFS, FL / ACCESSWIRE / November 18, 2016 / ?Today, Leone Asset Management (PINK SHEETS: LEON) announces they have acquired the controlling interest of Go Epic Health, Inc., an innovative nutritional supplement company based in Belleair Bluffs, Florida.
About Leone Asset Management
Leone Asset Management, Inc., is a multi-national, multi-industry conglomerate with subsidiary companies that operate in Health and Wellness in the U.S., Technology Development in India and Infrastructure development, agriculture management, and mineral exploration and export in Africa. For additional information, visit: www.leoneasset.com.
About Go Epic Health
Go Epic Health is a nutritional product holding company which owns the intellectual property and worldwide manufacturing and distribution rights to Cholesterade®, a natural cholesterol reducing product created by the late Dr. Robert Cade, creator of Gatorade®. Go Epic's wholly owned subsidiary, American Retail Alliance, markets and distributes Cholesterade® as well as other new and innovative consumer goods through the nation's largest retail pharmacy chain stores, free drug and health food stores, multi-level organizations, and product specific catalogs. Wholly owned subsidiary Eagle Labs is a product and contract manufacturing company specializing in manufacturing food, cosmetics, dietary supplements, liquid bottling and product formulation. For further information, please visit www.goepichealth.com and www.gocholesterade.com.
Forward-Looking Statements Disclosure:
This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," " plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matter that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.
Contact:
Woody Junot
President
Go Epic Health
(727) 581-1500
wjunot@goepichealth.com
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Benwahsauce
4年前
Renee
11年前
